Robert W. Baird Raises ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target to $31.00
ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) had its price target raised by Robert W. Baird from $28.00 to $31.00 in a report issued on Monday,Benzinga reports. The firm currently has an outperform rating on the biopharmaceutical company’s stock. A number of other research firms also recently issued reports on ACAD. BMO Capital Markets increased their […]
ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) had its price target raised by Robert W. Baird from $28.00 to $31.00 in a report issued on Monday,Benzinga reports. The firm currently has an outperform rating on the biopharmaceutical company’s stock. A number of other research firms also recently issued reports on ACAD. BMO Capital Markets increased their […]
